Factsheet H1 / 21
COMPANY PROFILE
Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Fresenius focuses on hospital operations. We also manage projects and provide services for hospitals and other health care facilities. More than 310,000 employees have dedicated themselves to the service of health in over 100 countries worldwide.
FRESENIUS GROUP IN FIGURES
€ in millions | H1/ 21 | H1 / 20 | Change | FY/ 20 | |||||
Sales and Earnings | |||||||||
Sales | 18,230 | 18,055 | 1% | 36,277 | |||||
EBIT 1 | 2,039 | 2,248 | -9% | 4,612 | |||||
Net income 1, 2 | 910 | 875 | 4% | 1,796 | |||||
Earnings per ord. share in € 1, 2 | 1.63 | 1.57 | 4% | 3.22 | |||||
Balance sheet and cash flow | |||||||||
Total assets | 69,655 | 5% | 66,646 | ||||||
Non-current assets | 52,754 | 4% | 50,874 | ||||||
Equity 3 | 27,131 | 4% | 26,023 | ||||||
Equity ratio 3 | 39.0% | - | 39.0 % | ||||||
Net debt / EBITDA 1, 4 | 3.60 | -- | 3.44 | ||||||
Investments 5 | 1,533 | 1,530 | 0% | 3,300 | |||||
Operating cash flow | 2,103 | 3,960 | -47% | 6,549 | |||||
Operating cash flow in % | |||||||||
of sales | 11.5% | 21.9% | -- | 18.1% | |||||
Profitability | |||||||||
EBIT margin 1 | 11.2% | 12.5% | -- | 12.7% | |||||
Return on equity after taxes | |||||||||
(ROE) 1, 2 | 10.3% | 10.5% | -- | 10.6% | |||||
Return on operating assets | |||||||||
(ROOA) 1 | 6.7% | 7.4% | -- | 7.3% | |||||
Return on invested capital | |||||||||
(ROIC) 1 | 6.1% | 6.6% | -- | 6.5% | |||||
Employees | 312,734 | 311,269 | |||||||
- Before special items
- Net income attributable to shareholders of Fresenius SE & Co. KGaA
- Including noncontrolling interests
- LTM average exchange rates for both net debt and EBITDA; pro forma closed acquisitions / divestitures
- Investments in property, plant and equipment, and intangible assets, acquisitions
GROUP STRUCTURE
The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.
32% 1 | 100% | 100% | 77% | ||||||||||||
Fresenius | |||||||||||||||
Fresenius | Fresenius | Fresenius | |||||||||||||
Medical Care | Kabi | Helios | Vamed | ||||||||||||
1 As of June 30, 2021
BUSINESS SEGMENTS
€ in millions | H1 / 21 | H1 / 20 | Change | FY / 20 | |||||||
Sales | 8,530 | 9,045 | -6% | 17,859 | |||||||
EBIT1 | 898 | 1,211 | -26% | 2,304 | |||||||
Sales | 3,516 | 3,467 | 1% | 6,976 | |||||||
EBIT2 | 574 | 581 | -1% | 1,095 | |||||||
Sales | 5,387 | 4,781 | 13% | 9,818 | |||||||
EBIT | 566 | 472 | 20% | 1,025 | |||||||
Sales | 1,033 | 974 | 6% | 2,068 | |||||||
EBIT | 12 | 1 | -- | 29 | |||||||
1 Reported
2 Before special items
- Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases. As of June 30, 2021 Fresenius Medical Care was treating 345,646 patients in 4,125 dialysis clinics. Along with its core business, the Renal Care Continuum, the company focuses on expanding in complementary areas and in the field of critical care.
- Fresenius Kabi offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients. The company is also a leading supplier of medical devices and trans fusion technology products. In the biosimilars business, Fresenius Kabi develops products with a focus on oncology and autoimmune diseases.
- Fresenius Helios is Europe's leading private hospital operator and is active as a provider of reproduction medicine worldwide. Helios Ger- many operates 89 acute care hospitals, ~130 outpatient clinics and
6 prevention centers. Quirónsalud operates 53 hospitals, including 6 in Latin America, 74 outpatient centers and ~ 300 occupational risk pre- vention centers. - Fresenius Vamed manages projects and provides services for hospitals and other health care facilities worldwide and is a leading post-acute care provider in Central Europe. The portfolio ranges along the entire value chain: from project development, planning, and turnkey con- struction, via maintenance and technical management to total opera- tional management.
SALES BY REGION
Latin America and
Others 6%
Asia-Pacific10%
North America 38%
SALES BY BUSINESS SEGMENT | |
Fresenius Vamed | |
5% | |
Fresenius Kabi | |
19% | |
Europe | 46% |
Fresenius Helios | |
29% | |
H1 / 21: € 18.2 billion | H1 / 21: €18.2 billion |
Fresenius Medical Care
47%
Factsheet H1 / 21 © Fresenius SE & Co. KGaA - Investor Relations & Sustainability | Page 1 / 2 |
FRESENIUS SHARE / ADR | RELATIVE SHARE PRICE PERFORMANCE | |||
FRESENIUS SHARE VS. DAX | ||||
Share | ||||
125 | ||||
Securities code no. | 578 560 | |
ISIN | DE0005785604 | |
Ticker symbol | FRE | |
ADR CUSIP | 35804M105 | |
ADR Ticker symbol | FSNUY | |
Number of shares (June 30, 2021) | 558,040,523 | |
Market capitalization (June 30, 2021) | €24.6 billion | |
120
115
110
105
100
95
90
31.12.2020 | 31.01.2021 | 28.02.2021 | 31.03.2021 | 30.04.2021 | 31.05.2021 | 30.06.2021 |
DAX | Fresenius share | ||||
ANALYST RECOMMENDATIONS | FINANCING MIX OF THE FRESENIUS GROUP |
Sell 6%
Commercial Paper 6%
Equity-neutral convertible bonds 2%
Equal-weight / Hold / Neutral 22%
As of June 30, 2021
Accumulate / Add / Buy /
Outperform /
Overweight 72%
Schuldschein loans 6%
Other financial liabilities 7%
Lease liabilities 23%
June 30, 2021: € 27,289 million |
Bonds 56%
DEVELOPMENT OF DIVIDENDS IN €
0.88 | |||||||||
0.84 | |||||||||
0.80 | |||||||||
0.75 | |||||||||
0.62 | |||||||||
0.55 | |||||||||
0.42 | 0.44 | ||||||||
0.37 | |||||||||
0.32 | |||||||||
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
GROUP OUTLOOK 2021
FY / 20 Base1 | Targets 2021 2 | |||
Low-to-mid | ||||
single-digit | ||||
Sales, growth (cc) | percentage | |||
€36,277 million | growth | |||
Low single-digit | ||||
Net income 3, growth (cc) | percentage | |||
€1,796 milion | growth | |||
- Before special items, including COVID-19 effects
- Before special items, including estimated COVID-19 effects
- Net income attributable to shareholders of Fresenius SE & Co. KGaA
For the outlook of the business segments please see the Investor News of July 30, 2021.
FINANCIAL CALENDAR
Dates | ||
Report on 3rd quarter 2021 | November 2, 2021 | |
Schedule updates, information on live webcasts, and other events at
www.fresenius.com/events-and-roadshows
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Wolfgang Kirsch
General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Stephan Sturm (Chairman), Dr. Sebastian Biedenkopf, Dr. Francesco De Meo, Rachel Empey, Rice Powell, Michael Sen, Dr. Ernst Wastler
Chairman of the Supervisory Board: Wolfgang Kirsch
CONTACT
Fresenius SE & Co. KGaA Else-Kröner-Straße1, 61352 Bad Homburg v. d. H. e-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
Markus Georgi | ||
Senior Vice President | Telephone: | +49 61 72 6 08-24 85 |
Investor Relations & Sustainability | Telefax: | +49 61 72 6 08-24 88 |
Follow us: |
Factsheet H1 / 21 © Fresenius SE & Co. KGaA - Investor Relations & Sustainability | Page 2 / 2 |
Attachments
- Original document
- Permalink
Disclaimer
Fresenius SE & Co. KGaA published this content on 02 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 August 2021 15:21:11 UTC.